BENZIMIDAZOLE AND AZABENZIMIDAZOLE IL-17 INHIBITOR COMPOUNDS

The present application discloses compounds having the following formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and X are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 medi...

Full description

Saved in:
Bibliographic Details
Main Authors VALDES, Alexander E, RHORER, Timothy B, BEHENNA, Douglas C, SONG, Kristen G, TANIS, Virginia M, GORDON, Deane, GOLDBERG, Steven D, WOODS, Craig R, LOSKOT, Steven A, SHIREMAN, Brock T, MCCARVER, Stefan J, XUE, Xiaohua
Format Patent
LanguageEnglish
French
Published 30.03.2023
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present application discloses compounds having the following formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and X are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease. La présente invention concerne des composés ayant la formule suivante (I) : ou des sels pharmaceutiquement acceptables de ceux-ci, formule dans laquelle R1, R2, R3, R4 et X sont tels que définis dans la description, ainsi que des procédés de fabrication et d'utilisation des composés de l'invention pour traiter ou atténuer un syndrome, un trouble et/ou une maladie médié(e) par l'IL-17.
Bibliography:Application Number: WO2022US76999